Skip to main content
Top
Published in: Clinical Pharmacokinetics 12/2017

01-12-2017 | Original Research Article

Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance

Authors: Iftekhar Mahmood, Million A. Tegenge

Published in: Clinical Pharmacokinetics | Issue 12/2017

Login to get access

Abstract

The objective of this study is to evaluate the predictive performance of several models to predict drug clearance in preterm and term neonates. Five models using different types of allometric and linear models were developed. Two sets of data were used to develop these models (data from preterm neonates to adults and data from preterm and term neonates). Models were also developed with (normalized to 70 kg) or without body weight normalization (body weight 1 kg). From the literature, clearance values for four drugs from neonates to adults were obtained. External data were used to evaluate the predictive performance of these models in preterm and term neonates. The results of the study indicated that (1) normalization to a standard body weight had no impact on the predictive performance of the models, (2) the model developed from preterm neonates to adults using fixed exponent 0.75 provided inaccurate estimate (overestimation) of drug clearance in neonates, (3) a far superior prediction of clearance was observed with the model when the exponents of allometry were estimated than the model using exponent 0.75, (4) linear models with the exception of the model with intercept provided comparable results to the estimated exponent model and were superior in their predictive performance to the model using exponent 0.75, and (5) when the models were developed from neonate data, the predictive performance of all models were similar. Overall, the study indicated that body weight normalization had no impact on the performance of model prediction, the exponents of allometry in pharmacostatistical models should be estimated rather than fixed, and more studies are needed to evaluate the suitability of linear models for the prediction of drug clearance in neonates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1–11.CrossRefPubMed Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet. 2006;45:1–11.CrossRefPubMed
2.
go back to reference Calvier EA, Krekels EH, Välitalo PA, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2017;56(3):273–85.CrossRefPubMed Calvier EA, Krekels EH, Välitalo PA, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2017;56(3):273–85.CrossRefPubMed
4.
go back to reference Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99:2927–33.CrossRefPubMed Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 2010;99:2927–33.CrossRefPubMed
5.
go back to reference El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol. 2006;46:433–42.CrossRefPubMed El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol. 2006;46:433–42.CrossRefPubMed
6.
go back to reference Trenque T, Simon N, Villena I, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol. 2004;57:735–41.CrossRefPubMedPubMedCentral Trenque T, Simon N, Villena I, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol. 2004;57:735–41.CrossRefPubMedPubMedCentral
7.
go back to reference Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45:1227–38.CrossRefPubMed Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 2006;45:1227–38.CrossRefPubMed
8.
go back to reference Laer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol. 2005;46:1322–30.CrossRefPubMed Laer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol. 2005;46:1322–30.CrossRefPubMed
9.
go back to reference Toublanc N, Sargentini-Maier ML, Lacroix B, et al. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet. 2008;47:333–41.CrossRefPubMed Toublanc N, Sargentini-Maier ML, Lacroix B, et al. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet. 2008;47:333–41.CrossRefPubMed
10.
go back to reference Paci A, Vassal G, Moshous D, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34:198–208.CrossRefPubMed Paci A, Vassal G, Moshous D, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34:198–208.CrossRefPubMed
11.
go back to reference Mahmood I. Prediction of drug clearance in premature and mature neonates, infants, and children ≤2 years of age: a comparison of the predictive performance of 4 allometric models. J Clin Pharmacol. 2016;56:733–9.CrossRefPubMed Mahmood I. Prediction of drug clearance in premature and mature neonates, infants, and children ≤2 years of age: a comparison of the predictive performance of 4 allometric models. J Clin Pharmacol. 2016;56:733–9.CrossRefPubMed
12.
go back to reference Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.CrossRefPubMedPubMedCentral Wang C, Peeters MY, Allegaert K, et al. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res. 2012;29:1570–81.CrossRefPubMedPubMedCentral
13.
go back to reference Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2014;77(1):149–59.CrossRefPubMed Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol. 2014;77(1):149–59.CrossRefPubMed
14.
go back to reference Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331–45.CrossRefPubMed Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet. 2012;51:331–45.CrossRefPubMed
15.
go back to reference Wang C, Sadhavisvam S, Krekels EH, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523–34.CrossRefPubMed Wang C, Sadhavisvam S, Krekels EH, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33:523–34.CrossRefPubMed
16.
go back to reference Staschen CM, Mahmood I. A population pharmacokinetic model of remifentanil in pediatric patients using body-weight-dependent allometric exponents. Drug Metabol Drug Interact. 2013;28:231–7.CrossRefPubMed Staschen CM, Mahmood I. A population pharmacokinetic model of remifentanil in pediatric patients using body-weight-dependent allometric exponents. Drug Metabol Drug Interact. 2013;28:231–7.CrossRefPubMed
17.
go back to reference Mahmood I, Staschen CM, Goteti K. Prediction of drug clearance in children: an evaluation of the predictive performance of several models. AAPS J. 2014;16:1334–43.CrossRefPubMedPubMedCentral Mahmood I, Staschen CM, Goteti K. Prediction of drug clearance in children: an evaluation of the predictive performance of several models. AAPS J. 2014;16:1334–43.CrossRefPubMedPubMedCentral
18.
go back to reference Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–64.CrossRefPubMedPubMedCentral Cella M, Zhao W, Jacqz-Aigrain E, et al. Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? Br J Clin Pharmacol. 2011;72:454–64.CrossRefPubMedPubMedCentral
19.
go back to reference Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255–62.CrossRefPubMed Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther. 2009;86:255–62.CrossRefPubMed
20.
go back to reference Krekels EH, van Hasselt JG, Tibboel D, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28:797–811.CrossRefPubMed Krekels EH, van Hasselt JG, Tibboel D, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28:797–811.CrossRefPubMed
Metadata
Title
Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance
Authors
Iftekhar Mahmood
Million A. Tegenge
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2017
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-017-0542-4

Other articles of this Issue 12/2017

Clinical Pharmacokinetics 12/2017 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees